CurrentAdvanced HealthPolicy N/A

Nebulized Medications Drug Use Criteria

Customize your policy alerts

Sign up for all advancedhealth policy alerts

Know when advancedhealth releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs pharmacy-benefit coverage of FDA-approved nebulized medications and establishes initial and renewal authorization requirements, including nebulizer access, appropriate diagnosis, medical necessity, and assessment of alternative inhaler delivery.

Policy Summary

PayerAdvanced Health

PolicyNebulized Medications Drug Use Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Last ReviewFeb 1, 2026

Next Review DateN/A

Key ActionSubmit a complete prior authorization request identifying the member's diagnosis and the requested nebulized medication.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

All FDA-approved nebulized medicationsPolicy scope

12 monthsMaximum initial authorization period

12 monthsMaximum renewal authorization period

3Explicit exclusion conditions

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAdvanced HealthPolicy N/A

Nebulized Medications Drug Use Criteria

Customize your policy alerts

Sign up for all advancedhealth policy alerts

Know when advancedhealth releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerAdvanced Health

PolicyNebulized Medications Drug Use Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Last ReviewFeb 1, 2026

Next Review DateN/A

Key ActionSubmit a complete prior authorization request identifying the member's diagnosis and the requested nebulized medication.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

All FDA-approved nebulized medicationsPolicy scope

12 monthsMaximum initial authorization period

12 monthsMaximum renewal authorization period

3Explicit exclusion conditions

OHA rules and OAR 410-122-0204

Regulatory framework

Coverage Criteria

Initial Therapy

Covered for initial authorization when all criteria below are met.

Initial authorization

Complete PA request: The request includes a complete prior authorization request, including the member's diagnosis and the requested nebulized medication.
Nebulizer access: The member has access to a nebulizer machine through current or prior Advanced Health approval, or documentation shows that a nebulizer is available for use in the home.
Members without a nebulizer must first meet Nebulizer Machine Drug Use Criteria.
Covered diagnosis: The member has a covered diagnosis consistent with OHA guidelines for nebulized therapy, such as COPD with airflow limitation confirmed by pulmonary function testing, moderate to severe asthma, bronchiectasis, cystic fibrosis, tracheostomy with secretion management, or another diagnosis requiring nebulized drug delivery.
FDA-approved formulation: The requested medication is an FDA-approved nebulized formulation for the member's diagnosis.
Alternative inhaler assessment
- Insufficient MDI/DPI: An MDI or DPI was attempted and found insufficient.
- MDI/DPI contraindication: An MDI or DPI is contraindicated for the member.
FDA-labeled regimen: The requested nebulized medication is consistent with the clinical indication for nebulized delivery and is requested at an FDA-approved dose and frequency.FDA-approved dose and frequency

Continuation Therapy

Covered for renewal authorization when all criteria below are met.

Renewal authorization

Continued nebulizer access: The member continues to have access to a nebulizer machine, either through an existing home nebulizer or approved equipment.
Continued clinical benefit: Documentation demonstrates continued clinical benefit from the nebulized medication, such as symptom improvement, reduced exacerbations, or improved pulmonary status.
FDA-labeled dose and quantity: The requested dose and quantity are within FDA labeling and consistent with clinical guidelines.

Coverage is not approved when the member does not have access to a nebulizer machine.

Coverage is not approved when an equivalent inhaled formulation is clinically appropriate and effective for the member.

Coverage is not approved when the requested medication is not FDA-approved for nebulized administration.

Provider Actions and Authorization Requirements

Prior Authorization

Initial Prior Authorization Required

Submit a complete prior authorization (PA) request for the nebulized medication. The request must identify the member’s diagnosis and the requested medication; incomplete requests do not meet initial authorization criteria.

Initial authorization requires all applicable criteria to be met.
Include the diagnosis and requested nebulized medication in the PA submission.

Prior Authorization

Renewal Authorization Requirements

For renewal authorization, document ongoing medical necessity and confirm that the member continues to have access to a nebulizer. Continued clinical benefit and compliant dose and quantity are also required.

Document continued nebulizer access.
Document ongoing clinical benefit, such as symptom improvement, fewer exacerbations, or improved pulmonary status.
Renewal approval may be issued for up to 12 months when criteria are met.

Policy Background

Nebulized medications are covered when nebulized delivery is medically necessary for a covered respiratory condition and the requested drug has an FDA-approved nebulized formulation. Medical necessity includes an appropriate diagnosis and a clinical need for nebulized delivery after considering alternative inhaled methods. Covered clinical contexts may include COPD with pulmonary-function-test-confirmed airflow limitation, moderate to severe asthma, bronchiectasis, cystic fibrosis, or tracheostomy-related secretion management.

Definitions

Access to a nebulizer machine

Current approvalAccess is established through current approval for a nebulizer machine under Advanced Health criteria.

Prior approvalAccess is also established through prior approval for a nebulizer machine under Advanced Health criteria.

Home equipmentAccess may be established by documentation that the member already has a nebulizer machine available for use in the home.

MDI/DPI

MDIA metered-dose inhaler, or MDI, is an inhaled delivery method that may be considered before nebulized therapy is authorized.

DPIA dry powder inhaler, or DPI, is an inhaled delivery method that may be considered before nebulized therapy is authorized.

Initial Therapy Criteria

Initial authorization

Initial approval requires completion of the following policy sequence.

1. Complete PA request: The request is submitted with a complete prior authorization request, including the diagnosis and the requested nebulized medication.
2. Nebulizer access: The member has access to a nebulizer machine, defined as current or prior approval for a nebulizer machine under Advanced Health criteria or documentation that a nebulizer machine is available for use in the home.
Members without a nebulizer must first meet Nebulizer Machine Drug Use Criteria.
3. Covered diagnosis: The member has a covered diagnosis consistent with OHA guidelines for nebulized therapy, including COPD with airflow limitation confirmed by pulmonary function testing, moderate to severe asthma, bronchiectasis, cystic fibrosis, tracheostomy with secretion management, or another diagnosis requiring nebulized drug delivery.

Continuation Criteria

Nebulized medication renewal

Renewal approval requires all criteria below.

1. Continued nebulizer access: The member continues to have access to a nebulizer machine, either an existing home nebulizer or approved equipment.
2. Continued clinical benefit: Documentation demonstrates continued clinical benefit from the nebulized medication, such as symptom improvement, reduced exacerbations, or improved pulmonary status.
3. FDA-labeled dose and quantity: The requested dose and quantity are within FDA labeling and consistent with clinical guidelines.

Step Therapy

Step	Requirement	Documentation or exception
1	Before initial nebulized medication authorization, attempt a metered-dose inhaler (MDI) or dry powder inhaler (DPI).	Document that the MDI or DPI was attempted and found insufficient. An MDI or DPI may be used without an attempted trial when it is contraindicated for the member.

Policy Summary

PayerAdvanced Health

PolicyNebulized Medications Drug Use Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Last ReviewFeb 1, 2026

Next Review DateN/A

Key ActionSubmit a complete prior authorization request identifying the member's diagnosis and the requested nebulized medication.

SourceLink

On This Page

Step Therapy

MDI/DPI Prerequisite

Before initial approval, document that an MDI or DPI was attempted and found insufficient or is contraindicated for the member. Poor technique alone is not treatment failure; provide inhaler education, with a spacer or mask when appropriate, when technique issues are identified.

Document MDI/DPI insufficiency or contraindication.
Address correct inhaler technique before concluding that treatment failure exists.

Documentation Required

Submit a Complete PA Request

Submit a complete PA request identifying both the covered diagnosis and the specific nebulized medication being requested. An incomplete request is denied for failure to meet initial criteria.

Include all required clinical information in the PA submission.
Identify the requested nebulized medication by name or sufficient description.

Documentation Required

Document Nebulizer Access

Document that the member has access to a nebulizer machine before medication approval. Qualifying access is established by current or prior approval for a nebulizer under Advanced Health criteria or documentation that a nebulizer is already available for use in the home.

Members who already possess a nebulizer do not need a simultaneous nebulizer-machine PA.
Members without access must first meet the Nebulizer Machine Drug Use Criteria.

Documentation Required

Diagnosis and Medical Necessity

Document a covered diagnosis consistent with OHA guidance for nebulized therapy and the clinical need for nebulized drug delivery. Examples include COPD with airflow limitation confirmed by PFT, moderate to severe asthma, bronchiectasis, cystic fibrosis, and tracheostomy with secretion management.

The diagnosis must support the need for nebulized delivery.
Other diagnoses may qualify when they require nebulized drug delivery and are consistent with OHA guidance.

Step Therapy

Assess Alternative Inhaler Delivery

Assess and document whether an MDI or DPI was attempted and insufficient or is contraindicated. When technique is the concern, document education on proper inhaler use and use of a spacer and/or mask when appropriate.

Poor inhaler technique alone does not establish treatment failure.
Document the alternative-delivery assessment in the initial PA.

Documentation Required

FDA-Labeled Nebulized Regimen

Document that the requested medication is FDA-approved for nebulized administration, appropriate for the member’s clinical indication, and prescribed at an FDA-approved dose and frequency.

The medication must be an FDA-approved nebulized formulation for the diagnosis.
The regimen must be consistent with the indication for nebulized delivery.
Initial approval may be issued for up to 12 months when all criteria are met.

Documentation Required

Document Continued Clinical Response

For renewal, document continued access to an existing home nebulizer or approved equipment and evidence of ongoing clinical benefit from the medication.

Examples of benefit include symptom improvement, reduced exacerbations, or improved pulmonary status.
Renewal is denied when continued access or benefit is not documented.

Unsupported block type: documentation

Denial Risk

Incomplete PA Request

Identify missing elements in an incomplete PA request and do not approve until the request is complete. An incomplete initial request is denied as not meeting criteria.

Check for the diagnosis and requested nebulized medication.
Also verify documentation of access, diagnosis, nebulized formulation, alternative inhaler assessment, and FDA-labeled regimen as applicable.

Denial Risk

No Nebulizer Access

Members without access to a nebulizer machine must first satisfy the criteria for approval of a nebulizer machine before the nebulized medication can be approved. Document current or prior equipment approval or qualifying home access when applicable.

No nebulizer access is an exclusion for nebulized medication approval.
A simultaneous machine PA is not required when the member already has an approved or available nebulizer.

Denial Risk

Unsupported Diagnosis

Approval is denied when the diagnosis or documented clinical need is not consistent with OHA guidance for nebulized therapy. The record must support a covered diagnosis requiring nebulized drug delivery.

Examples of potentially covered conditions include COPD with confirmed airflow limitation, moderate to severe asthma, bronchiectasis, cystic fibrosis, and tracheostomy with secretion management.
Unsupported diagnoses do not meet initial authorization criteria.

Denial Risk

Unapproved Formulation or Dosing

Do not request a formulation, indication, dose, or frequency that is not approved for nebulized administration. The requested medication must be an FDA-approved nebulized formulation and the regimen must match FDA labeling and the clinical indication.

Non-approved nebulized administration is excluded.
Non-approved dose or frequency does not meet initial or renewal criteria.

Denial Risk

Equivalent Inhaler Available

Approval may be denied when an equivalent inhaled formulation is clinically appropriate and effective for the member. Document why nebulized delivery remains medically necessary instead of an effective equivalent inhaler.

Consider whether an MDI or DPI is clinically appropriate and effective.
An equivalent effective inhaled formulation is an exclusion.

Step Therapy

Alternative Inhaler Requirement

Initial authorization requires documentation that an MDI or DPI was attempted and found insufficient or is contraindicated. If poor technique is identified, provide and document appropriate inhaler education before treating technique alone as a failure.

Document the failed or contraindicated alternative inhaler.
Consider a spacer and/or mask when appropriate.

Denial Risk

Renewal Criteria Not Met

Renewal is denied when the member lacks continued nebulizer access, ongoing clinical benefit is not documented, or the requested dose and quantity fall outside FDA labeling or clinical guidelines.

Verify access to an existing home nebulizer or approved equipment.
Document continued benefit.
Confirm FDA-labeled and guideline-consistent dose and quantity.

Alternative delivery assessmentBefore initial nebulized medication authorization, an MDI or DPI must be attempted and found insufficient, or be contraindicated for the member.

4. FDA-approved nebulized formulation: The requested medication is an FDA-approved nebulized formulation for the member's diagnosis.

5. Alternative inhaler assessment

MDI/DPI attempted and insufficient: A metered-dose inhaler or dry powder inhaler was attempted and found insufficient.
MDI/DPI contraindicated: A metered-dose inhaler or dry powder inhaler is contraindicated for the member.

6. FDA-labeled regimen: The requested nebulized medication is consistent with the clinical indication for nebulized delivery and is requested at an FDA-approved dose and frequency.FDA-approved dose and frequency

When all criteria are met, approve for up to 12 months.